Claims
- 1. Form I of (−)-6-chloro-4-cyclopropylethynyl-4-trifluoromethyl-1,4-dihydro-2H-3,1-benzoxazin-2-one which is characterized by an X-ray powder diffraction pattern as exhibited in FIG. 3.
- 2. Form II of (−)-6-chloro-4-cyclopropylethynyl-4-trifluoromethyl-1,4-dihydro-2H-3,1-benzoxazin-2-one which is characterized by an X-ray powder diffraction pattern as exhibited in FIG. 4.
- 3. Form III of (−)-6-chloro-4-cyclopropylethynyl-4-trifluoromethyl-1,4-dihydro-2H-3,1-benzoxazin-2-one which is characterized by an X-ray powder diffraction pattern as exhibited in FIG. 5.
- 4. Form III of (−)-6-chloro-4-cyclopropylethynyl-4-trifluoromethyl-1,4-dihydro-2H-3,1-benzoxazin-2-one as recited in claim 3, which is further characterized by a DSC curve as exhibited in FIG. 6.
- 5. Form III of (−)-6-chloro-4-cyclopropylethynyl-4-trifluoromethyl-1,4-dihydro-2H-3,1-benzoxazin-2-one as recited in claim 4, which is further characterized by a TG analysis as exhibited in FIG. 7.
- 6. Form I of (−)-6-chloro-4-cyclopropylethynyl-4-trifluoromethyl-1,4-dihydro-2H-3,1-benzoxazin-2-one characterized by crystallographic D-spacings of 14.5, 8.5, 8.0, 7.2, 6.7, 6.2, 5.2, 4.6, 4.4, 4.2 and 3.6 Angstroms.
- 7. Form I according to claim 6, having no detectable peaks for Form II or Form III in its X-ray powder diffraction pattern.
- 8. Form II of (−)-6-chloro-4-cyclopropylethynyl-4-trifluoromethyl-1,4-dihydro-2H-3,1-benzoxazin-2-one characterized by crystallographic D-spacings of 24.3, 13.9, 8.0, 6.9, 6.6, 5.5, 4.6, 4.5, 4.3, 4.2, 3.9, 3.6, 3.4, 3.3 and 3.2 Angstroms.
- 9. Form II according to claim 8, having no detectable peaks for Form I or Form III in its X-ray powder diffraction pattern.
- 10. Form III of (−)-6-chloro-4-cyclopropylethynyl-4-trifluoromethyl-1,4-dihydro-2H-3,1-benzoxazin-2-characterized by crystallographic D-spacings of 12.2, 8.1, 6.4, 6.1, 4.7, 4.3, 4.1, 4.0, 3.9, 3.8, 3.7, 3.6, 3.3, 3.2 and 3.0 Angstroms.
- 11. Form III according to claim 10, having no detectable peaks for Form I or Form II in its X-ray powder diffraction pattern.
Parent Case Info
This is a division of application Ser. No. 09/282,744 filed, now abandoned, Mar. 31, 1999, which is a divisional of U.S. application Ser. No. 09/008,824, filed Jan. 20, 1998, now U.S. Pat. No. 5,965,729, which claims the benefit of U.S. provisional application Serial Nos. 60/037,385, filed Feb. 5, 1997 and 60/042,807, filed Apr. 8, 1997.
US Referenced Citations (4)
Number |
Name |
Date |
Kind |
4518597 |
Narr et al. |
May 1985 |
A |
5519021 |
Young et al. |
May 1996 |
A |
5633405 |
Thompson et al. |
May 1997 |
A |
5663467 |
Thompson et al. |
Sep 1997 |
A |
Foreign Referenced Citations (8)
Number |
Date |
Country |
0 169 618 |
Jan 1986 |
EP |
0 582 455 |
Jan 1994 |
EP |
WO 9520389 |
Aug 1995 |
WO |
WO 9845278 |
Oct 1995 |
WO |
WO 9637457 |
Nov 1996 |
WO |
WO 9804535 |
Feb 1998 |
WO |
WO 9814436 |
Apr 1998 |
WO |
WO 9964405 |
Dec 1999 |
WO |
Non-Patent Literature Citations (3)
Entry |
T. L. Threifall, “Analysis of Organic Polymorphs”, Analyst, vol. 120, pp. 2435-2460 (Oct. 1995). |
D. Giron, “Thermal Analysis and calorimetric methods in the characterization of polymorphs and solvates”, Thermochimica Acta, vol. 248, pp. 1-59 (1995). |
A. S. Thompson et al., “Use of an Ephedrine Alkoxide to Mediate Enantioselective Addition of an Acetylide to a Prochiral Ketone: Assymmetric Synthesis of the Reverse Transcriptase Inhibitor L-743,726”, Tetrahedron Letters, vol. 36, No. 49, pp. 8937-8940 (1995). |
Provisional Applications (2)
|
Number |
Date |
Country |
|
60/037385 |
Feb 1997 |
US |
|
60/042807 |
Apr 1997 |
US |
Continuations (1)
|
Number |
Date |
Country |
Parent |
09/282744 |
Mar 1999 |
US |
Child |
10/000537 |
|
US |